Ambulatory resource utilization and cost for gout in United States

American Journal of Pharmacy Benefits

Volumn 5, Issue 2, 2013, Pages

  Li, Chenghui ^a   Martin, Bradley C ^a   Cummins, Dosha F ^b   Andrews, L Mon ^c   Frech Tamas, Feride ^c   Yadao, Anthony M ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANALGESIC AGENT; ANTIGOUT AGENT; COLCHICINE; COLCHICINE PLUS PROBENECID; CORTICOTROPIN; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; MINERALOCORTICOID; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID; SALICYLIC ACID DERIVATIVE;

ADULT; AGE; AGED; AMBULATORY CARE; ARTICLE; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; FEMALE; GOUT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; PRESCRIPTION; UNITED STATES;

EID: 84876542687     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kim KY, Schumacher HR, Hunsche E, Kim KY. A literature review of the epidemiology and treatment of acute gout. Clin Ther. 2003;25(6):1593-1617.
2. Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11(15)(suppl):S435-S442.
3. Brook RA, Forsythe A, Smeeding JE, Edwards NL. Chronic gout: epidemiology, disease, progression, treatment and disease burden. Curr Med Res Opin. 2010; 26(12):2813-2821.
4. Mikuls TR, Saag KG. New insights into gout epidemiology. Curr Opin Rheumatol. 2006;18(2):199-203.
5. Suresh E. Diagnosis and management of gout: a rational approach. Postgrad Med J. 2005;81(959):572-579.
6. Teng GG, Nair R, Saag KG. Pathophysiology, clinical presentation and treatment of gout. Drugs. 2006;66(12):1547-1563.
7. Schlesinger N. Management of acute and chronic gouty arthritis: present stateof- the-art. Drugs. 2004;64(21):2399-2416.
8. Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009;15(1):3-7.
9. Zhu Y, Panya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-3141.
10. Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population. Curr Med Res Opin. 2006;22(7):1381-1389.
11. Wu EQ, Patel PA, Yu AP, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm. 2008;14(2):164-175.
12. Schneider D, Appleton L, McLemore T. A reason for visit classification for ambulatory care. Vital Health Stat 2. 1979;(78):i-vi, 1-63.
13. Ambulatory and Hospital Care Statistics Branch, National Center for Health Statistics. 2007 National Hospital Ambulatory Medical Care Survey Micro-data File Documentation and 2007 National Ambulatory Medical Care Survey Micro-data File Documentation. http://www.cdc.gov/nchs/ahcd/ahcd_questionnaires.htm. Accessed January 21, 2011.
14. Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009;25(7):1711-1719.
15. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31(8): 1575-1581.
16. Jordan KM, Cameron JS, Snaith M, et al. British society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology. 2007;46(8):1372-1374.
17. Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout. Am J Manag Care. 2005;11(15)(suppl):S459-S464.
18. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006;12(2):61-65.
19. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008;67(7):960-966.
20. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925-934.
21. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010;6(1):30-38.
22. Braden JB, Russo J, Fan MY, et al. Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med. 2010;170(16):1425-1432.
23. Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318-328.
24. Weaver AL. Epidemiology of gout. Cleve Clin J Med. 2008;75(suppl 5):S9-S12.
25. Wu EQ, Patel PA, Mody RR, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol. 2009;36(5):1032-1040.
26. Baker DW, Stevens CD, Brook RH. Determinants of emergency department use: are race and ethnicity important? Ann Emerg Med. 1996;28(6):677-682.